Literature DB >> 6330164

Antibody response to dengue-2 vaccine measured by two different radioimmunoassay methods.

P L Summers, K H Eckels, J M Dalrymple, R M Scott, V A Boyd.   

Abstract

Two different radioimmunoassays were used to detect virus-specific antibodies in sera from human volunteers inoculated with an attenuated dengue type 2 (DEN-2) vaccine (PR-159/S-1). An indirect radioimmunoassay required purified DEN-2 virions for optimal reactivity but was 10 to 500 times more sensitive than neutralization or hemagglutination inhibition tests. An antibody capture radioimmunoassay was able to utilize crude antigens from either DEN-infected mouse brains or Aedes albopictus cell culture supernatants. When the two radioimmunoassay techniques were compared, the indirect method appeared to be the best assay for immunoglobulin G (IgG), whereas the antibody capture method was more sensitive for IgM detection. Selected human sera were examined for IgG, IgM, and IgA responses by using both techniques at various intervals after immunization. Although there were differences in magnitude, yellow fever immune as well as flavivirus nonimmune volunteers responded to DEN-2 vaccination by demonstrating IgG, IgM, and IgA antibody responses. In the nonimmune group, the most prevalent immunoglobulin detected was IgM, whereas in the yellow fever immune group, the predominant post-DEN-2 vaccine immunoglobulin was IgG. The preponderance of DEN-2-specific neutralizing antibodies were associated with either IgM or IgG according to the immune status of the volunteer. All classes of immunoglobulins attained maximum levels between 21 and 60 days postvaccination. In the majority of volunteers, IgM responses were relatively transient and could not be detected 6 months after immunization, whereas IgG and IgA antibodies were still detectable after this period.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6330164      PMCID: PMC271149          DOI: 10.1128/jcm.19.5.651-659.1984

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  24 in total

1.  Clinical and serologic response of man to immunization with attenuated dengue and yellow fever viruses.

Authors:  W R DORRANCE; J W FRANKEL; I GORDON; P R PATTERSON; R W SCHLESINGER; J W WINTER
Journal:  J Immunol       Date:  1956-11       Impact factor: 5.422

2.  Production and characterization of arbovirus antibody in mouse ascitic fluid.

Authors:  W E Brandt; E L Buescher; F M Hetrick
Journal:  Am J Trop Med Hyg       Date:  1967-05       Impact factor: 2.345

3.  Greater specificity of 19S than 7S antibodies on haemagglutination-inhibition tests with closely related group B arboviruses.

Authors:  E G Westaway
Journal:  Nature       Date:  1968-07-06       Impact factor: 49.962

4.  Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans.

Authors:  T P Monath
Journal:  Am J Epidemiol       Date:  1971-02       Impact factor: 4.897

5.  Persistence of rubellavirus-specific immunoglobulin M and immunoglobulin A antibodies: investigation of successive serum samples with lowered immunoglobulin G concentration.

Authors:  A Hornsleth; J Leerhoy; P Grauballe; H Spanggaard
Journal:  Infect Immun       Date:  1975-04       Impact factor: 3.441

6.  Hemagglutination-inhibiting immunoglobulin A antibody in the serum of patients with dengue hemorrhagic fever.

Authors:  S Inouye; S Matsuno; R Kono; N Sangkawibha; P Thongcharoen
Journal:  Jpn J Med Sci Biol       Date:  1980-06

7.  A plaque reduction test for dengue virus neutralizing antibodies.

Authors:  P K Russell; A Nisalak; P Sukhavachana; S Vivona
Journal:  J Immunol       Date:  1967-08       Impact factor: 5.422

8.  Dengue 2 vaccine: dose response in volunteers in relation to yellow fever immune status.

Authors:  R M Scott; K H Eckels; W H Bancroft; P L Summers; J M McCown; J H Anderson; P K Russell
Journal:  J Infect Dis       Date:  1983-12       Impact factor: 5.226

9.  Dengue-2 vaccine: virological, immunological, and clinical responses of six yellow fever-immune recipients.

Authors:  W H Bancroft; F H Top; K H Eckels; J H Anderson; J M McCown; P K Russell
Journal:  Infect Immun       Date:  1981-02       Impact factor: 3.441

10.  PRODUCTION OF IMMUNITY TO DENGUE WITH VIRUS MODIFIED BY PROPAGATION IN MICE.

Authors:  A B Sabin; R W Schlesinger
Journal:  Science       Date:  1945-06-22       Impact factor: 47.728

View more
  6 in total

1.  Evaluation of a commercially available immunoglobulin M capture enzyme-linked immunosorbent assay kit for diagnosing acute dengue infections.

Authors:  K R Porter; S Widjaja; H D Lohita; S H Hadiwijaya; C N Maroef; W Suharyono; R Tan
Journal:  Clin Diagn Lab Immunol       Date:  1999-09

2.  Expression of the structural proteins of dengue 2 virus and yellow fever virus by recombinant vaccinia viruses.

Authors:  Y S Hahn; E M Lenches; R Galler; C M Rice; J Dalrymple; J H Strauss
Journal:  Arch Virol       Date:  1990       Impact factor: 2.574

3.  Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors.

Authors:  Harry E Prince; Leslie H Tobler; Mary Lapé-Nixon; Gregory A Foster; Susan L Stramer; Michael P Busch
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

4.  Solid-phase antibody capture hemadsorption assay for detection of hepatitis A virus immunoglobulin M antibodies.

Authors:  P L Summers; D R Dubois; W H Cohen; P O Macarthy; L N Binn; M H Sjogren; R Snitbhan; B L Innis; K H Eckels
Journal:  J Clin Microbiol       Date:  1993-05       Impact factor: 5.948

Review 5.  Variation in dengue virus plaque reduction neutralization testing: systematic review and pooled analysis.

Authors:  Kaitlin Rainwater-Lovett; Isabel Rodriguez-Barraquer; Derek A T Cummings; Justin Lessler
Journal:  BMC Infect Dis       Date:  2012-09-28       Impact factor: 3.090

6.  The performance of RT-PCR compared with a rapid serological assay for acute dengue fever in a diagnostic laboratory.

Authors:  Timothy M Barkham; Youne Kow Chung; Kin Fai Tang; Eng Eong Ooi
Journal:  Trans R Soc Trop Med Hyg       Date:  2005-10-04       Impact factor: 2.184

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.